OSE Immunotherapeutics S.A.

https://www.ose-immuno.com

OSE Pharma is a European cancer immunotherapy company with a multi-epitope technology named Memopi® that directs the body’s immune system to generate a specific cytotoxic T response to prevent cancer cell growth. OSE Pharma’s lead product, Tedopi®, combines 10 “neo-epitopes” directed against five tumour associated antigens. In its most advanced application it is about to enter a pivotal Phase III study in patients with advanced non-small cell lung cancer (NSCLC) who express HLA-A2 and who have failed first line therapy. Tedopi® has orphan drug status in the USA and is considered as personalised medicine in Europe in HLA-A2 positive patients. OSE Pharma is also planning a new Phase II clinical trial in combination with another immunotherapy treatment in NSCLC. Tedopi® targets five tumour associated antigens (TAA), selected because their presence is linked to a poor prognosis and the severity of various cancers. Tedopi® contains a total of ten optimised epitopes, or “neo- epitopes”, designed on the binding of HLA-A2 and TCR. These neo-epitopes generate strong specific T cytotoxic responses that fight cancer and prevent tumour escape. (ISIN : FR0012127173 ; Mnémo : OSE). *

	Start	2014-09-21 existent
	End	2016-05-31 merged
	Group	OSE Immunotherapeutics (Group)
	Today	OSE Pharma S.A.
	Predecessor	Effimune SAS
	Industry	Memopi® multi-epitope technology
	Industry 2	Tedopi® cancer immunotherapy
	Person	Poirier, Nicolas (OSE Immunotherapeutics 202210– CEO + CSO before CSO before Effimune + Tcl Pharma)
	Person 2	Costantini, Dominique (OSE Pharma 201504 CEO + Co-founder + former CEO + Co-founder of BioAlliance Pharma in 1997)

	Region	Nantes
	Country	France
	Street	22 boulevard Benoni Goullin
	City	44200 Nantes
	Tel	+33-2-2829-1010
		Address record changed: 2024-01-05

Basic data	Employees	n. a.
	Currency	EUR
	Profit	-5,584,000 (2015-12-31)
	Cash	15,131,000 (2015-12-31)

		* Document for »About Section«:

		Record changed: 2024-02-12